Skip to content
10-Q

Quarterly Report

GlobeStar Therapeutics Corp

0001161697-24-000285

← back to feed
Filed
Jun 28, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2024 · Jun 21, 2024 1.24B sh
Operating Cash Flow Q2 2024 · Mar 31, 2024 −$55.18K
Operating Cash Flow Q2 2024 · Mar 31, 2023 −$92.89K
Stockholders Equity Q2 2024 · Mar 31, 2024 −$1.47M
Stockholders Equity Q2 2024 · Dec 31, 2023 −$1.53M
Stockholders Equity Q2 2024 · Sep 30, 2023 −$1.43M
Stockholders Equity Q2 2024 · Mar 31, 2023 −$1.29M
Stockholders Equity Q2 2024 · Dec 31, 2022 −$1.24M
Stockholders Equity Q2 2024 · Sep 30, 2022 −$1.19M
Current Liabilities Q2 2024 · Mar 31, 2024 $1.62M
Current Liabilities Q2 2024 · Sep 30, 2023 $1.43M
Total Liabilities Q2 2024 · Mar 31, 2024 $1.62M
Total Liabilities Q2 2024 · Sep 30, 2023 $1.43M
Current Assets Q2 2024 · Mar 31, 2024 $147.71K
Total Assets Q2 2024 · Mar 31, 2024 $147.71K
Net Income Q2 2024 · Mar 31, 2024 −$174.96K
Net Income Q2 2024 · Mar 31, 2024 −$338.72K
Net Income Q2 2024 · Dec 31, 2023 −$163.76K
Net Income Q2 2024 · Mar 31, 2023 −$150.24K
Net Income Q2 2024 · Mar 31, 2023 −$316.15K
Net Income Q2 2024 · Dec 31, 2022 −$165.91K
Operating Income Q2 2024 · Mar 31, 2024 −$167.58K
Operating Income Q2 2024 · Mar 31, 2024 −$323.45K
Operating Income Q2 2024 · Mar 31, 2023 −$142.06K
Operating Income Q2 2024 · Mar 31, 2023 −$297.3K
Stock Issued Q2 2024 · Feb 28, 2022 6M sh